Details of the Drug Combinations

General Information of This Drug (ID: DMOQ9H1)

Drug Name
Tremelimumab   DMOQ9H1
Indication
Disease Entry ICD 11 Status REF
Hepatocellular carcinoma 2C12.02 Approved [1]
Malignant mesothelioma 2C26.0 Phase 3 [2]
Solid tumour/cancer 2A00-2F9Z Phase 3 [3]
Drug Type
Monoclonal antibody

List of Combinatorial Drugs (CBD) Containing This Drug

1 Clinical Trial Drug Combination(s) Consisting of This drug
DrugCom Name DrugCom ID Component Drug Indication REF
Tremelimumab + MEDI0562 DC7CZNO MEDI0562 Solid tumour/cancer [4]
------------------------------------------------------------------------------------

References

1 FDA Approved Drug Products from FDA Official Website. 2022. Application Number: 761289.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8462).
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)